Sanofi boosts case for Toujeo with real-world data presentation

Real-world data presented by France’s Sanofi (Euronext: SAN) show that the firm’s once-daily long-acting basal analogue Toujeo (gla-300) is associated with statistically significant improvements in HbA1c in patients with type 1 diabetes.

Toujeo, a more concentrated version of the company’s insulin workhorse Lantus (insulin glargine), was approved by the US Food and Drug Administration in early 2015.

The primary objective of the study was to describe the change in HbA1c levels from baseline to six months following initiation of gla-300 in patients with type 1 diabetes. The data show a statistically significant reduction in this regard.